Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS

Globeflex Capital L P purchased a new position in Bioventus Inc. (NASDAQ:BVS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 165,865 shares of the company’s stock, valued at approximately $1,566,000. Globeflex Capital L P owned 0.20% of Bioventus as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BVS. Engine Capital Management LP bought a new stake in shares of Bioventus during the 1st quarter valued at $2,876,000. Sei Investments Co. increased its stake in shares of Bioventus by 160.7% in the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after acquiring an additional 178,539 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Bioventus by 14.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after acquiring an additional 107,930 shares in the last quarter. Hillsdale Investment Management Inc. lifted its position in Bioventus by 148.7% during the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after acquiring an additional 401,230 shares during the period. Finally, Fifth Third Bancorp purchased a new position in Bioventus during the 1st quarter valued at about $1,478,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Stock Down 2.5%

NASDAQ:BVS opened at $14.02 on Tuesday. The firm has a market cap of $1.18 billion, a P/E ratio of 18.21, a P/E/G ratio of 1.83 and a beta of 0.63. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. Bioventus Inc. has a fifty-two week low of $6.26 and a fifty-two week high of $15.89. The firm has a 50-day simple moving average of $12.01 and a two-hundred day simple moving average of $10.18.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The firm had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Analysts predict that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Craig Hallum reiterated a “buy” rating and set a $18.00 target price on shares of Bioventus in a report on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday, August 17th. Canaccord Genuity Group upped their price target on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Finally, Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.80.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.